Abstract
Abstract not available.
Highlights
To assess clearance rate relative to baseline, cumulative disease area clearance, and complete clearance rate by lesion size in treated lesions only in patients treated with ALA-PDT for AKs on the upper extremities
AK lesion count and mapping were performed at baseline and at weeks 4, 8, and 12; lesion size and grade were assessed at baseline and at weeks 8 and 12
Post hoc assessments included mean AK clearance rate compared to baseline, cumulative disease area clearance, and subgroup analysis of complete clearance rate by lesion size
Summary
Actinic keratoses (AKs) are precancerous, dysplastic epidermal lesions that may progress to squamous cell carcinoma (SCC)[1]. Aminolevulinic acid (ALA) 20% solution photodynamic therapy (PDT) is indicated for targeted treatment of AK on the face, scalp, and upper extremities[2]. In a phase 3, randomized, evaluator-blinded, vehicle-controlled trial (NCT02137785), ALA 20% solution–PDT at baseline and week 8 using lesion-targeted treatment and a 3-hour occluded incubation was superior to vehicle (VEH)–PDT for AK clearance of the upper extremities3 — The study assessed response of the entire field to treatment, including new AKs present at follow-up, in calculations of clearance rates
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
